All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
Introducing
Now you can personalise
your MDS Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Luspatercept-aamt is a first-in-class erythroid maturation agent. It reduces the inhibitory effect of the SMAD2-SMAD3 pathway on red cell maturation, which is reported to be increased in bone marrow cells of patients with myelodysplastic syndromes (MDS) with ineffective erythropoiesis.1
The placebo-controlled phase III MEDALIST trial (NCT02631070) evaluated luspatercept in transfusion-dependent patients who do not respond to erythropoiesis-stimulating agents. A higher proportion of patients treated with luspatercept (38%) showed red blood cell transfusion independence for ≥ 8 weeks within the first 24 weeks compared with the placebo group (13%; p < 0.001). Additionally, a higher percentage of patients treated with luspatercept showed ≥ 12 weeks of independence in the first 24 weeks (28% vs 8% in luspatercept vs placebo group, respectively; p < 0.001) and 48 weeks (33% vs 12% in luspatercept vs placebo group, respectively; p < 0.001) of the trial compared with the placebo group.1
Treatment-emergent adverse events of Grade 3 or 4 were reported in 42.5% of patients who received luspatercept vs 44.7% of patients who received placebo. The most common all-grade adverse events (occurring in ≥ 10% of patients) included fatigue, diarrhea, asthenia, nausea, dizziness, and back pain. Adverse events incidence reduced after the fourth cycle and was not associated with dose adjustment but led to treatment discontinuation in 8% of patients.1
With the favorable results from the MEDALIST trial, the U.S. Food and Drug Administration (FDA) approved luspatercept on April 3, 2020, for the treatment of anemia failing an erythropoiesis-stimulating agent and requiring two or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk MDS with ring sideroblasts (MDS-RS), or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).2
Soon after the FDA approval, on June 25, 2020, the European Medicines Agency also approved luspatercept for its use in Europe for the treatment of adult patients with transfusion-dependent anemia due to very low, low, and intermediate-risk MDS-RS, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.3
Subscribe to get the best content related to MDS delivered to your inbox